All Updates

All Updates

icon
Filter
Funding
Seamless Therapeutics raises EUR 11.8 million in seed funding
Human Gene Editing
Mar 16, 2023
This week:
Product updates
AWS launches Automated Reasoning checks to combat AI hallucinations
Generative AI Infrastructure
Today
Funding
Soda Health raises USD 50 million in oversubscribed Series B funding to scale operations
Health Benefits Platforms
Yesterday
Funding
StretchDollar raises USD 6 million in seed funding to expand platform
Health Benefits Platforms
Yesterday
Partnerships
ThoroughCare integrates care management software with PointClickCare for coordinated healthcare delivery
Age Tech
Yesterday
Product updates
NovelSweets project develops protein-based sweetener 'X3'
Alternative Ingredients
Yesterday
Partnerships
Amazon partners with Anthropic to build world's largest AI supercomputer 'Project Rainier'
Foundation Models
Yesterday
Partnerships
Amazon partners with Anthropic to build world's largest AI supercomputer 'Project Rainier'
Generative AI Infrastructure
Yesterday
Product updates
AWS launches multi-agent collaboration capabilities for Amazon Bedrock
Generative AI Infrastructure
Yesterday
Product updates
AWS announces Trainium2 chip general availability and upcoming Trainium3 chip at re:Invent 2024 conference
Machine Learning Infrastructure
Yesterday
Product updates
AWS announces Trainium2 chip general availability and upcoming Trainium3 chip at re:Invent 2024 conference
Generative AI Infrastructure
Yesterday
Human Gene Editing

Human Gene Editing

Mar 16, 2023

Seamless Therapeutics raises EUR 11.8 million in seed funding

Funding

  • Gene editing company Seamless Therapeutics has raised EUR 11.8 million (USD 12.5 million) in a seed financing round co-led by Wellington Partners and Forbion. The raised funds included non-dilutive financing from BMBF GO-Bio, an initiative by the German government. 

  • The Germany-based company follows a gene-editing approach that develops designer recombinases: programmable enzymes that are reportedly capable of editing substantial portions of genes, unlike natural recombinases that work on very specific target sequences. The company plans to use the funding to further develop its technology platform and expand its presence in the EU and US.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.